Rivipansel: Phase II data
A double-blind Phase II trial in patients ages 12-18 years with sickle cell disease who were experiencing vaso-occlusive crisis showed that GMI-1070 missed the primary endpoint of improving time to discharge and resolution of vaso-occlusive crisis vs. standard of care (p=0.06). GMI-1070 did lead to a >=50% reduction in time to transition to oral pain medications vs. standard of care (p=0.037). Safety results were consistent with prior findings with GMI-1070 in adults. Data were presented at the American Society of Pediatric Hematology Oncology meeting in Chicago.
GlycoMimetics previously reported data from a Phase II trial with GMI-1070 in 76 hospitalized patients ages 12-60 years with sickle cell disease who were experiencing vaso-occlusive crisis (see BioCentury, April 22, 2013 & Jan. 6, 2014). ...